Finanzen von Pharming Group NV (PHAR)PHARPharming Group NV

In the context of the broader market, PHAR competes directly with industry leaders such as CTMX and GYRE. With a market capitalization of $829.52M, it holds a leading position in the sector. When comparing efficiency, PHAR's gross margin of N/A stands against CTMX's 100.00% and GYRE's 92.41%. Such benchmarking helps identify whether Pharming Group N.V. is trading at a premium or discount relative to its financial performance.

Pharming's Q2 2026 revenue estimate was downgraded to $88.28 million from $376.20 million, reflecting market caution. However, the expected earnings per share for the full year has improved from $0.03 to $0.05, indicating potential profitability improvements.